According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Organogenesis improperly billed the federal government for its Affinity (a wound covering product) and PuraPly XT (an antimicrobial barrier) products by, among other things, setting the price for those products multiple times higher than similar products;
- the Company improperly induced doctors to use its Affinity and PuraPly XT products through lucrative reimbursements;
- as a result of all the foregoing, the Company’s revenue and profits derived from its Affinity and PuraPly XT products were at least in substantial part unsustainable; and
- as a result, the Company’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.